Rep. Julie Johnson Sells Johnson & Johnson (NYSE:JNJ) Shares

Representative Julie Johnson (D-Texas) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on December 18th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Philip Morris International (NYSE:PM) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Bank of America (NYSE:BAC) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Republic Services (NYSE:RSG) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Xcel Energy (NASDAQ:XEL) on 12/18/2025.

Johnson & Johnson Trading Down 0.3%

NYSE:JNJ traded down $0.76 on Friday, reaching $218.81. 9,957,493 shares of the stock traded hands, compared to its average volume of 7,239,795. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $220.11. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The company’s 50 day moving average is $205.82 and its 200-day moving average is $186.95. The firm has a market capitalization of $527.18 billion, a price-to-earnings ratio of 21.12, a price-to-earnings-growth ratio of 2.25 and a beta of 0.34.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on JNJ. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday. Barclays increased their price objective on Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 30th. HSBC reaffirmed a “buy” rating and issued a $240.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, December 10th. Raymond James Financial increased their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. Finally, Loop Capital set a $190.00 price objective on Johnson & Johnson in a report on Wednesday, October 22nd. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $213.33.

Institutional Trading of Johnson & Johnson

Several institutional investors and hedge funds have recently made changes to their positions in JNJ. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson during the third quarter valued at approximately $26,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson during the 3rd quarter valued at approximately $28,000. Evolution Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $27,000. Semmax Financial Advisors Inc. boosted its position in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares in the last quarter. Finally, Turning Point Benefit Group Inc. bought a new position in shares of Johnson & Johnson in the 3rd quarter worth about $41,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.